SCHEMBL16740762

SCHEMBL16740762

Cc1nc2ccccc2n1-c1nc(N)nc(Nc2ccc(C(C)C)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 12/20 0.51
PIK3CA P42336 12/20 0.51
PIK3CB P42338 12/20 0.51
PIK3CG P48736 12/20 0.51
MTOR P42345 11/20 0.51
BMI1 P35226 6/20 0.47
TNKS O95271 1/20 0.44
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740753 0.88 PIK3CD (0.53) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16740776 0.88 BMI1 (0.59) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16740749 0.86 TUBB4A (0.56) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16740712 0.84 BMI1 (0.62) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16748479 0.83 BMI1 (0.62) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16740792 0.83 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16748480 0.83 BMI1 (0.64) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16748438 0.81 PIK3CD (0.61) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16748475 0.81 CHRNA7 (0.51) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16748419 0.81 PIK3CA (0.45) PIK3CDPIK3CAPIK3CBPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B PIK3CD 2974/4885PIK3CA 3534/4885PIK3CB 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.